Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production

Dezhi Song, Zhen Cao, Zaibing Liu, Jennifer Tickner, Heng Qiu, Chao Wang, Kai Chen, Ziyi Wang, Shiwu Dong, Jiake Xu

Research output: Contribution to journalArticle

6 Citations (Scopus)
7 Downloads (Pure)

Abstract

Osteoporosis is a metabolic disease characterized by osteopenia and bone microstructural deterioration. Osteoclasts are the primary effector cells that degrade bone matrix and their abnormal function leads to the development of osteoporosis. Reactive oxygen species (ROS) accumulation during cellular metabolism promotes osteoclast proliferation and differentiation, therefore, playing an important role in osteoporosis. Cistanche deserticola polysaccharide (CDP) possesses antitumor, anti-inflammatory, and antioxidant activity. However, the impact of CDP on osteoclasts is unclear. In this study, tartrate-resistant acid phosphatase staining, immunofluorescence, reverse transcription-polymerase chain reaction, and western blot analysis were utilized to demonstrate that CDP inhibited osteoclastogenesis and hydroxyapatite resorption. In addition, CDP also inhibited the expression of osteoclast maker genes including Ctsk, Mmp9, and Acp5 and had no effect on receptor activator of nuclear factor κB (RANK) expression. Mechanistic analyses revealed that CDP increases the expression of antioxidant enzymes to attenuate RANKL-mediated ROS production in osteoclasts and inhibits nuclear factor of activated T cells and mitogen-activated protein kinase activation. These results suggest that CDP may represent a candidate drug for the treatment of osteoporosis caused by excessive osteoclast activity.

Original languageEnglish
Pages (from-to)9674-9684
Number of pages11
JournalJournal of Cellular Physiology
Volume233
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Cistanche
Osteoclasts
Bone Resorption
Osteogenesis
Polysaccharides
Reactive Oxygen Species
Bone
Osteoporosis
Antioxidants
NFATC Transcription Factors
Bone Matrix
Metabolic Bone Diseases
Polymerase chain reaction
Metabolic Diseases
Transcription
Durapatite
Cytoplasmic and Nuclear Receptors
Acid Phosphatase
Mitogen-Activated Protein Kinases
Metabolism

Cite this

@article{c0b5cd92eee44f89bbf10e5bd1bde479,
title = "Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production",
abstract = "Osteoporosis is a metabolic disease characterized by osteopenia and bone microstructural deterioration. Osteoclasts are the primary effector cells that degrade bone matrix and their abnormal function leads to the development of osteoporosis. Reactive oxygen species (ROS) accumulation during cellular metabolism promotes osteoclast proliferation and differentiation, therefore, playing an important role in osteoporosis. Cistanche deserticola polysaccharide (CDP) possesses antitumor, anti-inflammatory, and antioxidant activity. However, the impact of CDP on osteoclasts is unclear. In this study, tartrate-resistant acid phosphatase staining, immunofluorescence, reverse transcription-polymerase chain reaction, and western blot analysis were utilized to demonstrate that CDP inhibited osteoclastogenesis and hydroxyapatite resorption. In addition, CDP also inhibited the expression of osteoclast maker genes including Ctsk, Mmp9, and Acp5 and had no effect on receptor activator of nuclear factor κB (RANK) expression. Mechanistic analyses revealed that CDP increases the expression of antioxidant enzymes to attenuate RANKL-mediated ROS production in osteoclasts and inhibits nuclear factor of activated T cells and mitogen-activated protein kinase activation. These results suggest that CDP may represent a candidate drug for the treatment of osteoporosis caused by excessive osteoclast activity.",
keywords = "bone resorption, Cistanche deserticola polysaccharide, MAPK, osteoclast, reactive oxygen species",
author = "Dezhi Song and Zhen Cao and Zaibing Liu and Jennifer Tickner and Heng Qiu and Chao Wang and Kai Chen and Ziyi Wang and Shiwu Dong and Jiake Xu",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/jcp.26882",
language = "English",
volume = "233",
pages = "9674--9684",
journal = "Journal Cellular Physiology",
issn = "0021-9541",
publisher = "John Wiley & Sons",
number = "12",

}

Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production. / Song, Dezhi; Cao, Zhen; Liu, Zaibing; Tickner, Jennifer; Qiu, Heng; Wang, Chao; Chen, Kai; Wang, Ziyi; Dong, Shiwu; Xu, Jiake.

In: Journal of Cellular Physiology, Vol. 233, No. 12, 01.12.2018, p. 9674-9684.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production

AU - Song, Dezhi

AU - Cao, Zhen

AU - Liu, Zaibing

AU - Tickner, Jennifer

AU - Qiu, Heng

AU - Wang, Chao

AU - Chen, Kai

AU - Wang, Ziyi

AU - Dong, Shiwu

AU - Xu, Jiake

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Osteoporosis is a metabolic disease characterized by osteopenia and bone microstructural deterioration. Osteoclasts are the primary effector cells that degrade bone matrix and their abnormal function leads to the development of osteoporosis. Reactive oxygen species (ROS) accumulation during cellular metabolism promotes osteoclast proliferation and differentiation, therefore, playing an important role in osteoporosis. Cistanche deserticola polysaccharide (CDP) possesses antitumor, anti-inflammatory, and antioxidant activity. However, the impact of CDP on osteoclasts is unclear. In this study, tartrate-resistant acid phosphatase staining, immunofluorescence, reverse transcription-polymerase chain reaction, and western blot analysis were utilized to demonstrate that CDP inhibited osteoclastogenesis and hydroxyapatite resorption. In addition, CDP also inhibited the expression of osteoclast maker genes including Ctsk, Mmp9, and Acp5 and had no effect on receptor activator of nuclear factor κB (RANK) expression. Mechanistic analyses revealed that CDP increases the expression of antioxidant enzymes to attenuate RANKL-mediated ROS production in osteoclasts and inhibits nuclear factor of activated T cells and mitogen-activated protein kinase activation. These results suggest that CDP may represent a candidate drug for the treatment of osteoporosis caused by excessive osteoclast activity.

AB - Osteoporosis is a metabolic disease characterized by osteopenia and bone microstructural deterioration. Osteoclasts are the primary effector cells that degrade bone matrix and their abnormal function leads to the development of osteoporosis. Reactive oxygen species (ROS) accumulation during cellular metabolism promotes osteoclast proliferation and differentiation, therefore, playing an important role in osteoporosis. Cistanche deserticola polysaccharide (CDP) possesses antitumor, anti-inflammatory, and antioxidant activity. However, the impact of CDP on osteoclasts is unclear. In this study, tartrate-resistant acid phosphatase staining, immunofluorescence, reverse transcription-polymerase chain reaction, and western blot analysis were utilized to demonstrate that CDP inhibited osteoclastogenesis and hydroxyapatite resorption. In addition, CDP also inhibited the expression of osteoclast maker genes including Ctsk, Mmp9, and Acp5 and had no effect on receptor activator of nuclear factor κB (RANK) expression. Mechanistic analyses revealed that CDP increases the expression of antioxidant enzymes to attenuate RANKL-mediated ROS production in osteoclasts and inhibits nuclear factor of activated T cells and mitogen-activated protein kinase activation. These results suggest that CDP may represent a candidate drug for the treatment of osteoporosis caused by excessive osteoclast activity.

KW - bone resorption

KW - Cistanche deserticola polysaccharide

KW - MAPK

KW - osteoclast

KW - reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=85050608983&partnerID=8YFLogxK

U2 - 10.1002/jcp.26882

DO - 10.1002/jcp.26882

M3 - Article

VL - 233

SP - 9674

EP - 9684

JO - Journal Cellular Physiology

JF - Journal Cellular Physiology

SN - 0021-9541

IS - 12

ER -